## PRELIMINARY AMENDMENT CIP of USSN 08/424,983

Application Continuation-in-part of U.S. Patent Serial No. 08/053,030, filed April 23, 1993 (now abandoned). --Page 13, line 21, change "Adjuvant)" to -- Adjuvant --; line 23, change "Adjuvant)" to -- Adjuvant --; line 23, change "Immunolon I" to -- IMMUNOLON I--; line 28, change "Triton X-100" to -- TRITON X-100 (polyethylene glycol tert-octylphenyl ether) --. Page 14, Nine 16, change "Immunolon I" to -- IMMUNOLON I --; line 20, change "Triton X-100" to -- TRITON X-100--; Tine 23, change "Triton X-100" to -- TRITON X-100--; ŧ[] line 25, change "Triton X-100" to -- TRITON X-100--; and Ħ Mine 28, change "Triton X-100" to --TRITON X-100--. :[] "RAP-42-OVAF<sub>2</sub>#1hc-" change to U Page 15, line 12, -- RAP-42-OVAF2#1hc --; line 14, after "methodology." insert -- Hybridoma  $RAP-42-OVAF_2\#1hc$  was deposited under the terms of the Budapest Treaty at the American Type Culture Collection, 10801 University Boulevard, Manassas, VIRGINIA 20110-2209, USA, on March 10, 1994, and was granted accession number HB 11568. 1 --; and line 19, change "(Immunolon I)" to --(IMMUNOLON I)--. Page 16, line 23, change "\Immunolon I)" to -- (IMMUNOLON I)--. IN THE CLAIMS

Please cancel Claims 1-32.

## PRELIMINARY AMENDMENT CIP of USSN 08/424,983

## Please add the following new claims:

Claim 33. A \monoclonal antibody having binding specificity for a rapamycin, wherein said antibody is obtained using an comprising a molecule selected from the immunogen rapamycin having linking the consisting of a group at having linking 42 position, rapamycin a group at the 31 position, and rapamycin having a linking group at both the 42 position and the \$1 position.

Claim 34. The monoclonal antibody of Claim 33, wherein said molecule is a rapamycin having a linking group at the 42 position.

Claim 35. The monoclonal antibody of Claim 34, wherein said molecule is a rapamycin 42-ester with a dicarboxylic acid.

Claim 36. The monoclonal antibody of Claim 35, wherein said dicarboxylic acid is succinic acid.

Claim 37. The monoclonal antibody of Claim 33, wherein said molecule is conjugated to an immunogenic protein selected from the group consisting of keyhole limpet hemocyanin and ovalbumin.

Claim 38. The monoclonal antibody of Claim 33, wherein said immunogen is a rapamycin 42-ester with succinic acid conjugated to ovalbumin.

Claim 39. The monoclonal antibody of Claim 33, wherein said antibody is produced by hybridoma RAP-42-OVAF $_2$ #1hc (ATCC No. 11568).

Claim 40. Hybridoma RAP-42-OVAF2#1hc (ATCC No. 11568). --

(T

I.

1111